References
- de Villiers TJ. Should women be screened for osteoporosis at midlife? Climacteric 2018;21:239–42
- World Health Organization. Fact Sheet. Cancer. 2018. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed March 20, 2018]
- International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx [last accessed March 20, 2018]
- Cancer Research UK. Bodyweight facts and evidence. 15th July 2016. Available from: http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/bodyweight-and-cancer/bodyweight-facts-and-evidence#bodyweight_facts1 [last accessed March 20, 2018]
- Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA: Cancer J Clin 2014;64:186–94
- National Cancer Institute. Precision medicine in cancer treatment. 3rd Oct, 2017. Available from: https://www.cancer.gov/about-cancer/treatment/types/precision-medicine [last accessed March 20, 2018]
- 't Hoen E, Access to cancer treatment: a study of medicine pricing issues with recommendations for improving access to cancer medication. A report prepared for OXFAM. 2nd May 2014. Available from: http://apps.who.int/medicinedocs/documents/s21758en/s21758en.pdf [last accessed March 20, 2018]
- Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. 1968. Available from: http://apps.who.int/iris/bitstream/10665/37650/17/WHO_PHP_34.pdf
- Canfell K. Cervical screening in HPV-vaccinated populations. Climacteric 2018;21:227–34
- Alliance for Cervical Cancer Prevention. Natural history of cervical cancer: even infrequent screening of older women saves lives. April 2003. Available from: http://screening.iarc.fr/doc/RH_natural_history_of_cc_fs.pdf [last accessed March 20, 2018]
- Australian Government Department of Health. National Cervical Screening Program. 2018. Available from: http://www.health.gov.au/internet/screening/publishing.nsf/Content/cervical-screening-1 [last accessed March 20, 2018]
- Bennett RL, Sellars SJ, Moss SM. Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. Br J Cancer 2011;104:571–7
- Kavanagh AM, Mitchell H, Farrugia H, Giles GG. Monitoring interval cancers in an Australian mammographic screening programme. J Med Screen 1999;6:139–43
- Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009;302:1685–92
- Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987–98
- Cupit-Link MC, Kirkland JL, Ness KK, et al. Biology of premature ageing in survivors of cancer. ESMO Open 2017;2:e000250
- Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011;(1):CD001877
- Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ 2013;346:f385
- NHS Choices. Breast Cancer Screening. 7th January 2015. Available from: https://www.nhs.uk/conditions/breast-cancer-screening/why-its-offered/ [last accessed March 20, 2018]
- BreastScreen Victoria. The Facts. 2018. Available from: https://www.breastscreen.org.au/Breast-Screening/The-Facts#sm.00000iv878g7fue88qe6luzr8ghth [last accessed March 20, 2018]
- Ghanouni A, Meisel SF, Hersch J, Waller J, Wardle J, Renzi C. Information on ‘overdiagnosis’ in breast cancer screening on prominent United Kingdom- and Australia-oriented health websites. PLoS One 2016;11:e0152279
- Hersch J, Barratt A, Jansen J, et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet 2015;385:1642–52
- Biller-Andorno N, Juni P. Abolishing mammography screening programs? A view from the Swiss medical board. N Engl J Med 2014;370:1965–7
- Barratt A, Jorgensen KJ, Autier P. Reform of the national screening mammography program in France. JAMA Intern Med 2018;178:177–8
- U.S. National Library of Medicine. ClinicalTrials.gov. Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET). 18th Dec 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02926911 [last accessed March 20, 2018]
- Jacklyn G, Morrell S, McGeechan K, et al. Carcinoma in situ of the breast in New South Wales, Australia: current status and trends over the last 40 year. Breast 2018;37:170–8
- DCIS 411. Keeping patient perspectives at the forefront of DCIS research. 12th Jan 2018. Available from: https://dcis411.com/2018/01/12/keeping-patient-perspectives-at-the-forefront-of-dcis-research/ [last accessed March 20, 2018]
- Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016;2:1023–9
- Saini V, Garcia-Armesto S, Klemperer D, et al. Drivers of poor medical care. Lancet 2017;390:178–90